Novartis shares down as failed cholesterol drug study increases pipeline pressure

Shares of Novartis fell 3.3% on Monday morning after its ​cholesterol drug failed in a ‌closely watched study, casting fresh doubt on the therapeutic approach and ​raising the stakes for the ​Swiss dr...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。